Just wonder what people like Rob Thomas, Chairman and Non-executive Director AM, BEc, MSAA, SF Fin at Starpharma can bring to the table for Biotron he's been around and has impresive credentials but what can all this achieve for bit. Mr Thomas has a strong background in financial services and is a non executive director on a number of listed Healthcare companies in Australia and the United States. He has more than 35 years’ experience in the securities industry with Potter Partners (now UBS), County Natwest and Citigroup. He is currently Chairman of Gragher Capital Securities and the NSW State Library. He is the immediate past non-executive Chairman of Heartware International Inc and remains a non-executive director of that company and is also a director of ASX listed REVA Medical Inc., Virgin Australia Limited and Biotron Limited. Rob holds a Bachelor of Economics from Monash University and is a fellow of the Securities Institute of Australia. He is also a Master Stockbroker and is a Fellow of the Institute of Company Directors.
BIT Price at posting:
2.8¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)